Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen

Inclusion Criteria: * Histologic or cytologic diagnosis of stage IIIB/IV NSCLC * ECOG PS: 0,1 * Unidimensional or bi-dimensional measurable disease * Receive prior treatment including first-line platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor * Evidence of disease progression * Life expectancy \>12 weeks * Neutrophils \> 1.5 109/l, Platelets \> 100 109/l, Hemoglobin \> 9g/dl, Total bilirubin \< 1.5 UNL, AST (SGOT) and ALT (SGPT) \< 2.5 UNL, Alkaline phosphatases \< 5 UNL, Creatinine \< 1 UNL Exclusion Criteria: * Pre-existing hemoptysis of a severity \> grade 3 by NCI CTCAE criteria within 4 weeks prior to study entry * Uncontrolled hypertension * CHF, angina or arrhythmias * LVEF \< 1 UNL * Existing a second malignancy within 5 years * Infected with HIV